Tristel posts another year of strong growth

A set of excellent results are expected for the year to June 30, but a trading update today yielded only a slight rise in the company's UK stock. The share price was around 3p higher to 378p shortly after the markets opened.

Based in Snailwell near Newmarket, Tristel confirmed another year of significant growth with results expected to be in line with market expectations and the company's own performance targets.

Tristel said it continued to see strong demand for its infection prevention products, with second half revenues increasing by 15 per cent on a constant currency basis.

Revenues for the year were up 11 per cent to £46.5 million in line with the company's performance target for revenue growth (an annual average of 10-15 per cent over three years).

Tristel reports strong growth (23 per cent) in adjusted profit before tax which is expected to be no less than £10.1m, in line with expectations (FY 2024: £8.2m).

Tristel continues to be debt free and cash generative. Cash balances at June 30 were £12.8m (£11.8m).

CEO Matt Sassone said: “As I approach the one year mark as CEO, we are pleased to have delivered another year of strong growth, fully aligned with our strategic targets. Demand for our infection prevention technologies remains robust across all regions, including our newly established North American markets.

“Achieving 11 per cent revenue growth and a 23 per cent uplift in adjusted profit before tax reflects both the resilience of our business model and the commitment of our global team.

“We have further strengthened our Board with the addition of our new CFO, Anna Wasyl, who will join us in September, and we look forward to capitalising on her expertise as we enter the next phase of growth. We remain debt-free, cash-generative, and confident in our ability to sustain this momentum as we look to the year ahead.”